Business Wire

TIME-OUT-GROUP-PLC

7.10.2021 01:03:11 CEST | Business Wire | Press release

Share
Time Out reveals the World’s Coolest Neighbourhoods right now

Time Out has revealed that Nørrebro in Copenhagen tops its fourth annual World’s Coolest Neighbourhoods list: the cultural and culinary hotspots that are leading the way as we begin to emerge from the pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211006005865/en/

Since 2018, Time Out’s World’s Coolest Neighbourhoods list has been collated using responses from the Time Out Index survey, combined with the expertise of Time Out’s international network of local editors and city experts. This year, more than 27,000 global city-dwellers nominated their city’s coolest, most underrated and most culturally exciting neighbourhood. To create and rank the final list, Time Out’s local expert editors and writers rated neighbourhoods for great vibes, food, drink, nightlife, emerging culture, community spirit and resilience. They also considered sustainability, innovative green initiatives and other factors that promote stress-free living.

Nørrebro is a diverse district where history meets ultramodern architecture on the northern side of Copenhagen’s lakes, and it truly has it all. In a city proudly known for its food and drink scene, Nørrebro has seen a flurry of new openings this year from bakeries to natural wine bars, all with a focus on local, seasonal (and often foraged) produce. The neighbourhood was host to the city’s Pride march this summer, when WorldPride came to Copenhagen – the most significant LGBTQ+ event in the world. In a year where community has been more important than ever, Nørrebro has no shortage of innovative initiatives including Nørrebrogade’s Car-Free Sunday where traffic is swapped for live music and flea markets, and Usynglige Stier (‘Invisible Paths’) an interactive art exhibition that brings fun and a splash of colour to the neighbourhood’s most vulnerable areas.

Caroline McGinn, Time Out’s Global Editor-in-Chief, said: “Time Out’s annual list of the World’s Coolest Neighbourhoods is a love letter to the city at its most joyful and surprising. It celebrates the hyperlocal places where cities of the future are being made up, on the spot. In the last year, grassroots community culture has been vital to preserving the health and optimism of city-dwellers and the restaurants, bars, galleries and culture spots that make cities such a crucible of invention and social life. It’s inspiring to see how much energy there is in these areas, where communities have come together, hung out and made new stuff, as well as supported other businesses and each other. You’ve probably never heard of most of the neighbourhoods on the list but these are places where a ‘better normal’ is emerging. I can’t wait to visit.”

Read the full list at www.timeout.com/coolest-neighbourhoods-in-the-world

1. Nørrebro, Copenhagen

2. Andersonville, Chicago

3. Jongno 3-ga, Seoul

4. Leith, Edinburgh

5. Station District, Vilnius

6. Chelsea, New York

7. XI District, Budapest

8. Ngor, Dakar

9. Sai Kung, Hong Kong

10. Richmond, Melbourne

11. Neukölln, Berlin

12. Centro, Medellín

13. Dalston, London

14. Silver Lake, Los Angeles

15. Dublin 8, Dublin

16. Zoloti Vorota, Kiev

17. Noord, Amsterdam

18. Villeray, Montreal

19. Surry Hills, Sydney

20. Ancoats, Manchester

21. Sagene, Oslo

22. Old Xuhui, Shanghai

23. Centro, Mexico City

24. Gràcia, Barcelona

25. Saúde, Rio de Janeiro

26. Kemptown, Brighton

27. Sololaki, Tbilisi

28. Brickell, Miami

29. Ouseburn, Newcastle

30. Barranco, Lima

31. Chamberí, Madrid

32. Vinohrady, Prague

33. Katong, Singapore

34. Anjos, Lisbon

35. Daikanyama, Tokyo

36. Haut-Marais, Paris

37. Al Bateen, Abu Dhabi

38. Foz, Porto

39. Central Square, Boston

40. Mount Pleasant, Vancouver

41. Jamestown, Accra

42. Centro, Oaxaca

43. Mouassine, Marrakech

44. Dubai Marina, Dubai

45. Kadikoy, Istanbul

46. Poblacion, Manila

47. Ari, Bangkok

48. Koregaon Park, Pune

49. El Arrayán, Santiago

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye